Abnormal cellular immune responses during acquired zinc deficiency.
The cellular immune response of a 17-year-old decerebrate male with acquired zinc deficiency was studied. He had been fed a commercial formula which contained 7.6 mg zinc per kilogram. His caloric intake had been inadequate as judged by his cachexia. A detailed pretreatment nutritional assessment (five separate observations) which included total serum protein and globulins, albumin, folate, vitamins A, B2, C, ceruloplasmin, and plasma zinc, copper, iron, and total iron binding capacity revealed that the patient was deficient only in zinc and calories. His plasma zinc was 41 +/- 5 microgram/d1 compared with our laboratory norm of 89 +/- 9 microgram/d1 for young adult males. Cellular immunity was assessed by delayed skin reactivity to dinitrochlorobenzene and by in vitro lymphocyte transformation studies. Before zinc therapy the patient rendered a negative skin reaction to dinitrochlorobenzene, and the ability of his lymphocytes to undergo blast transformation in response to mitogen stimulation was significantly depressed with a stimulation index of 4.7 +/- 0.8 as compared with 139.1 +/- 77.3  for controls. Within 3 weeks after zinc therapy (22.7 mg zinc per day) he demonstrated a positive delayed skin reaction to dinitrochlorobenzene and a normal lymphocyte response stimulation index = 205.5 +/- 42.6 versus 199.3 +/- 58.2 for control). In addition, a pretreatment facial seborrhea and a decubitus ulcer rapidly healed.
D000293:Adolescent; D003655:Decerebrate State / Q000276:immunology*; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004137:Dinitrochlorobenzene / Q000494:pharmacology; D004750:Enteral Nutrition; D005148:Facial Dermatoses / Q000188:drug therapy; D005526:Food, Formulated; D006197:Hair / Q000378:metabolism; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced; D007111:Immunity, Cellular / Q000187:drug effects; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D010835:Phytohemagglutinins / Q000494:pharmacology; D003668:Pressure Ulcer / Q000188:drug therapy; D012867:Skin / Q000276:immunology; D015032:Zinc / Q000172:deficiency* / Q000627:therapeutic use
D004137:Dinitrochlorobenzene; D010835:Phytohemagglutinins; D015032:Zinc